BNP Paribas Financial Markets Cuts Position in OPKO Health, Inc. (NASDAQ:OPK)

BNP Paribas Financial Markets decreased its stake in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 79.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,849 shares of the biotechnology company's stock after selling 195,118 shares during the quarter. BNP Paribas Financial Markets' holdings in OPKO Health were worth $76,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in OPK. Altshuler Shaham Ltd purchased a new stake in shares of OPKO Health during the fourth quarter worth about $2,082,000. Norges Bank purchased a new stake in shares of OPKO Health during the fourth quarter worth about $1,657,000. Marshall Wace LLP grew its position in shares of OPKO Health by 856.5% during the fourth quarter. Marshall Wace LLP now owns 921,487 shares of the biotechnology company's stock worth $1,355,000 after purchasing an additional 825,143 shares in the last quarter. Barclays PLC grew its position in shares of OPKO Health by 68.7% during the fourth quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after purchasing an additional 373,032 shares in the last quarter. Finally, Essential Planning LLC. bought a new position in OPKO Health during the fourth quarter valued at approximately $506,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 200,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $1.74 per share, with a total value of $348,000.00. Following the purchase, the chief executive officer now owns 213,501,448 shares of the company's stock, valued at approximately $371,492,519.52. The trade was a 0.09% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 700,000 shares of company stock valued at $1,123,000 in the last ninety days. Insiders own 49.69% of the company's stock.

OPKO Health Trading Up 1.9%

Shares of NASDAQ:OPK traded up $0.03 during trading on Thursday, hitting $1.37. The company had a trading volume of 2,250,817 shares, compared to its average volume of 3,843,452. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -7.21 and a beta of 1.42. OPKO Health, Inc. has a one year low of $1.19 and a one year high of $2.04. The company has a fifty day simple moving average of $1.39 and a two-hundred day simple moving average of $1.53. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. OPKO Health's revenue for the quarter was down 13.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) earnings per share. As a group, equities analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on OPK shares. Barrington Research reissued an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. JPMorgan Chase & Co. started coverage on OPKO Health in a research note on Friday, April 25th. They set a "neutral" rating for the company. Wall Street Zen lowered OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. Finally, HC Wainwright reissued a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.